Page 65 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

Data extraction
Independent reviewers (I.A. and A.J.) evaluated relevant articles for eligibility. Moreover, discussion resolved any disagreement on included studies. The Randomized clinical trial study design, number of patients enrolled in the study, treatment regimen options, overall survival(OS), PDL-1 expression status, the follow up (media) and the OOR. Included studies by one reviewer (I.A.) and later verified by a second reviewer (A.J.) to confirm their precision and accuracy.
Data analysis.
Data were presented using descriptive analysis. Means and standard deviation were used to described continuous outcomes, interquartile range and median were used. Proportions and frequencies were also used to present specific findings. Odds ratios for response rate, HR for OSS, and PFS was stated and if they report with confidence intervals (CIs). We could not perform quantitative analysis (Meta- analysis) because of a limited number of studies.
Results.
Qualitative and systematic review analysis
The search texts identified 705 articles and an additional study published after the end date for inclusion but being of particular relevance. After removing duplicate studies, we assessed all titles and abstracts. Finally, 17publications were identified as potentially germane and were retrieved for full-text appraisal. An additional study, outside the predetermined time-interval but of general relevance was included as well. Agreeing to these inclusion benchmarks, seven randomized phase 1–3 clinical trials were carefully chosen for evidence analysis. Randomised clinical trials (5) on ten sorts of treatment, including 979 patients, all the clinical trial are multicentric and announced in English. Trials using immune checkpoints (PDL-1, CTLA-4, and PD-1). Drugs used in the clinical trial include Tremelimumab, Pembrolizumab (MK-3475), Nivolumab (MSB0010718C, Durvalumab (MEDI4736) and Atezolizumab (MPDL3280A) as seen in Table. 1. The first screening of this literature suggested that these immuno-checkpoint-targeting agents were associated with manageable levels of toxicity and potential clinical benefit in
Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
3
59
63